{"filings":[{"id":759241,"accession_number":"0001193125-26-249692","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2026-06-01T11:00:19+00:00","items":["3.02","3.03","5.03","5.02","9.01"],"status":"ready","headline":"Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.","Stockholders holding 57.1% of shares approved via written consent on April 28, 2026.","Appointed Stephen W. Webster (former CFO of Spark Therapeutics) and Nina Kjellson (Canaan Partners GP) to Board.","Board reduced from six to five directors; each new director received an option to purchase 13,587 shares.","Common stock trading on OTC Pink under symbol ELOX will begin split-adjusted on June 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90741,"accession_number":"0001193125-26-201408","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve reverse split range, authorized share reduction, equity plan amendments via written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ratified amendment to 2018 Equity Plan: shares available increased to 20M, ISO limit to 30M.","Approved restated plan extending ISO grant period, further raising ISO limit, extending evergreen provision.","Approved reverse stock split at ratio 1:2 to 1:20, with board discretion for up to one year.","Approved decrease in authorized common shares from 500M to 100M, effective at board discretion within one year.","Votes cast by 4,324,964 shares (57.1% of outstanding) on April 28, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133272,"accession_number":"0001104659-25-076933","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Lindsay Androski resigns from Eloxx board effective August 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lindsay Androski notified the Board of her resignation, effective immediately on August 6, 2025.","Resignation was not due to any disagreement with the Company's operations, policies, or practices.","No replacement director has been announced; board size reduced accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186029,"accession_number":"0001104659-24-109521","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eloxx reprices CEO's 196,880 options to $0.0001, accelerates vesting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Sumit Aggarwal holds 196,880 options with weighted avg exercise price $0.90 repriced to $0.0001.","Options granted under 2018 Equity Incentive Plan; exercisable in full as of Oct 16, 2024 regardless of vesting.","New exercise price set to $0.0001, the closing OTC price on the repricing date.","Option repricing approved by Board on Oct 16, 2024; amendment approved by Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202608,"accession_number":"0001104659-24-080251","cik":1035354,"company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Eloxx enters $3.2M debt amendment with Hercules and Domicilium; Royalty obligations up to $53M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tranche 2 Advance of $3.175M provided under Sixth Amendment to Hercules loan; Bridge Loan of $288k also made.","Conversion options: Tranche 1A/1B debt can convert into equity if Qualified Financing ≥$7M occurs before April 2025.","Royalty Agreement: 33% of first three Almirall milestones and 25% of subsequent milestones, capped at $53M, plus 0.75% of ELX-02 and 0.50% of ZKN-013 revenue.","Amended Securities Purchase Agreement grants anti-dilution rights to SD MF for 15 months.","Reporting covenant for FY2023 audited financials extended to November 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1188190.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}